In recent years, the development of domestic innovative drugs has continued to be hot, with more and more enterprises entering the innovative drug track, the intensification of industry competition has become inevitable, and the target pile and track congestion have become the general trend
.
Among them, the field of tumor is a very serious field of "involution", especially PD-1/L1, which is one of the very hot targets in recent years, and the listed varieties are all new drugs
.
It is worth noting that although the "involution" of pharmaceutical companies in new tumor drugs is constantly intensifying, they are also ushering in more and more new breakthroughs
.
On October 19, it was reported that the clinical trial application of anti-tumor bispecific antibody injection (SIM0348) submitted by Simcere Pharmaceutical has been accepted by the State Food and Drug Administration and is intended to be used to carry out clinical trials
for the treatment of advanced malignant tumors.
According to the data, SIM0348 is a humanized TIGIT/PVRIG bispecific antibody injection developed by Simcere Pharmaceutical, which can specifically bind two new immune checkpoint proteins of human TIGIT and PVRIG at the same time to improve the anti-tumor activity
of immune cells.
On October 10, Salubris Pharmaceutical announced that its application for clinical trials of SAL008 injection, an innovative anti-tumor biological drug independently developed by the People's Republic of China (NMPA), was accepted
by the China National Medical Products Administration (NMPA).
SAL008 is a fusion protein of IL-15/IL-15Rα complex and anti-CTLA-4 antibody, developed by SalubrisBio, a subsidiary of Salubis Pharmaceuticals, for the treatment
of advanced solid tumors.
The drug has initiated a Phase 1 clinical study in Europe and is currently undergoing patient enrollment
.
A few days ago, Genor Biopharma announced that its GB263T Phase I/II clinical trial reached the first patient administration in China for the treatment of
patients with advanced non-small cell lung cancer and other solid tumors.
It is understood that GB263T is the world's first EGFR/cMET/cMET trispecific antibody, and this clinical trial has been carried out in Australia and completed the first human administration
.
In addition, Hengrui Pharmaceutical also recently issued an announcement that its subsidiary, Shanghai Hengrui Pharmaceutical Co.
, Ltd.
, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration on SHR-A2102 injection, and will carry out clinical trials
in the near future.
Data show that SHR-A2102 binds to the target antigen on the surface of tumor cells, so that the drug is swallowed into the cell and releases small molecule toxins to kill tumor cells, which is clinically intended for the treatment of
malignant tumors.
After inquiry, there are currently no similar products approved for marketing in China, and there is no relevant sales data
.
Up to now, SHR-A2102 injection related projects have invested a total of about 26.
2 million yuan
in research and development expenses.
In general, it is obvious from the new progress in the research and development of a large number of new anti-tumor drugs that the innovative research and development of anti-tumor innovative drugs in China is advancing
rapidly.
In fact, the number of tumor patients in China is huge, with the upgrading of residents' consumption level and the advancement of medical technology, the scale of the anti-tumor drug market has been continuously expanding, and it is expected to reach 683.
1 billion yuan
in 2030.
Attracted by the huge market prospects, the industry expects that the enthusiasm of domestic pharmaceutical companies for innovation will continue to rise, and more domestic anti-tumor new drugs will continue to emerge
in the future.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
